Chemistry

Helicobacter pylori

Clarithromycin

Gastroenterology

Antibiotics

Internal medicine

Amoxicillin

Pharmacology

Medicine

Biochemistry

Vonoprazan can be considered as a potent and long-acting PPI with some potential advantages over traditional PPIs. Both PPIs and vonoprazan therapy can be tailored to achieve more or less acid inhibition allowing the degree of acid suppression to be tailored to the need. Current clarithromycin- and vonoprazan-containing H pylori eradication therapies likely result in misuse of clarithromycin or metronidazole.30Shiotani A. Lu H. Dore M.P. Graham D.Y. Treating Helicobacter pylori effectively while minimizing misuse of antibiotics.Cleve Clin J Med. 2017; 84: 310-318Crossref PubMed Scopus (49) Google Scholar Vonoprazan offers the promise of being able to reliably achieve an intragastric pH of >5 and possibly >6, which may make it useful as an adjuvant to preventing recurrent bleeding after endoscopic hemostasis or for H pylori eradication therapy and to reliably achieve high cure rates with amoxicillin plus an antisecretory agent therapy. Vonoprazan may also assist in the management of fat malabsorption in patien...

Update on the Use of Vonoprazan: A Competitive Acid Blocker